PMC:7408073 / 83847-84261 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T472","span":{"begin":15,"end":23},"obj":"Body_part"}],"attributes":[{"id":"A472","pred":"fma_id","subj":"T472","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"In addition to cytokine profile (such as IL-10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulation and activation of positive feedback loops (see Figure 2)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2878","span":{"begin":41,"end":46},"obj":"Gene"},{"id":"2879","span":{"begin":331,"end":335},"obj":"Gene"},{"id":"2894","span":{"begin":150,"end":158},"obj":"Species"},{"id":"2895","span":{"begin":241,"end":251},"obj":"Species"},{"id":"2896","span":{"begin":252,"end":260},"obj":"Species"},{"id":"2905","span":{"begin":49,"end":61},"obj":"Disease"},{"id":"2906","span":{"begin":63,"end":74},"obj":"Disease"},{"id":"2907","span":{"begin":82,"end":93},"obj":"Disease"},{"id":"2908","span":{"begin":104,"end":112},"obj":"Disease"},{"id":"2909","span":{"begin":117,"end":140},"obj":"Disease"},{"id":"2910","span":{"begin":164,"end":176},"obj":"Disease"},{"id":"2911","span":{"begin":200,"end":212},"obj":"Disease"},{"id":"2912","span":{"begin":230,"end":237},"obj":"Disease"}],"attributes":[{"id":"A2878","pred":"tao:has_database_id","subj":"2878","obj":"Gene:3586"},{"id":"A2879","pred":"tao:has_database_id","subj":"2879","obj":"Gene:59272"},{"id":"A2894","pred":"tao:has_database_id","subj":"2894","obj":"Tax:9606"},{"id":"A2895","pred":"tao:has_database_id","subj":"2895","obj":"Tax:2697049"},{"id":"A2896","pred":"tao:has_database_id","subj":"2896","obj":"Tax:9606"},{"id":"A2906","pred":"tao:has_database_id","subj":"2906","obj":"MESH:D013610"},{"id":"A2907","pred":"tao:has_database_id","subj":"2907","obj":"MESH:D007022"},{"id":"A2908","pred":"tao:has_database_id","subj":"2908","obj":"MESH:C000657245"},{"id":"A2909","pred":"tao:has_database_id","subj":"2909","obj":"MESH:D000860"},{"id":"A2910","pred":"tao:has_database_id","subj":"2910","obj":"MESH:D006973"},{"id":"A2911","pred":"tao:has_database_id","subj":"2911","obj":"MESH:D006973"},{"id":"A2912","pred":"tao:has_database_id","subj":"2912","obj":"MESH:D000860"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In addition to cytokine profile (such as IL-10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulation and activation of positive feedback loops (see Figure 2)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T484","span":{"begin":82,"end":93},"obj":"Disease"},{"id":"T485","span":{"begin":104,"end":112},"obj":"Disease"},{"id":"T486","span":{"begin":241,"end":249},"obj":"Disease"},{"id":"T487","span":{"begin":241,"end":245},"obj":"Disease"}],"attributes":[{"id":"A484","pred":"mondo_id","subj":"T484","obj":"http://purl.obolibrary.org/obo/MONDO_0005468"},{"id":"A485","pred":"mondo_id","subj":"T485","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A486","pred":"mondo_id","subj":"T486","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A487","pred":"mondo_id","subj":"T487","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"In addition to cytokine profile (such as IL-10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulation and activation of positive feedback loops (see Figure 2)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1010","span":{"begin":361,"end":371},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"In addition to cytokine profile (such as IL-10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulation and activation of positive feedback loops (see Figure 2)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T29103","span":{"begin":41,"end":43},"obj":"Chemical"},{"id":"T71125","span":{"begin":138,"end":140},"obj":"Chemical"}],"attributes":[{"id":"A4614","pred":"chebi_id","subj":"T29103","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A69049","pred":"chebi_id","subj":"T29103","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A26558","pred":"chebi_id","subj":"T71125","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"In addition to cytokine profile (such as IL-10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulation and activation of positive feedback loops (see Figure 2)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T411","span":{"begin":0,"end":414},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In addition to cytokine profile (such as IL-10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulation and activation of positive feedback loops (see Figure 2)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T145","span":{"begin":63,"end":74},"obj":"Phenotype"},{"id":"T146","span":{"begin":82,"end":93},"obj":"Phenotype"},{"id":"T147","span":{"begin":117,"end":124},"obj":"Phenotype"},{"id":"T148","span":{"begin":230,"end":237},"obj":"Phenotype"}],"attributes":[{"id":"A145","pred":"hp_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/HP_0001649"},{"id":"A146","pred":"hp_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/HP_0002615"},{"id":"A147","pred":"hp_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/HP_0012418"},{"id":"A148","pred":"hp_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/HP_0012418"}],"text":"In addition to cytokine profile (such as IL-10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulation and activation of positive feedback loops (see Figure 2)."}